8-K - 60 Degrees Pharmaceuticals, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

On February 11, 2026, 60 Degrees Pharmaceuticals, Inc. received notification from Nasdaq that it had regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). Consequently, the previously scheduled hearing was cancelled, and the Company's common stock will continue to be listed on The Nasdaq Capital Market.

Key Takeaways

1The Company regained compliance with Nasdaq Listing Rule 5550(a)(2) regarding the minimum bid price requirement on February 11, 2026.

2Nasdaq staff had previously determined to delist the Company's common stock and warrants due to a failure to maintain a minimum bid price of $1.00 per share for 30 consecutive business days.

3The Company had appealed the delisting determination and paid a $20,000 hearing fee, which stayed the suspension pending the Panel's decision.

4The Nasdaq Hearings Panel meeting scheduled for February 19, 2026, has been cancelled.

5The matter regarding the listing non-compliance is now closed, and the common stock will continue to trade on The Nasdaq Capital Market.

Current Report Details

Event Type

Other Event

Disclosure

Voluntary

Variant

8-K

Items Reported

8.01

Other Events As previously disclosed, on January 20, 2026, 60 Degrees Pharmaceuticals, Inc. (the “Company”) received a written notice (the “Notice”) from the Na

Other Event

$1.00$20.0K

Exhibits (1)

8-K

CURRENT REPORT